Purple Biotech (PPBT) Non Operating Interest Expenses (2014 - 2026)

Purple Biotech (PPBT) has reported Non Operating Interest Expenses for 12 consecutive years, with $9000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 145.0% year-over-year to $9000.0 in Q2 2026; TTM through Jun 2026 was $259000.0, a 43.33% decrease from a year earlier, with the FY2025 full-year figure at $982000.0, up 103.31% from the prior year.
• Non Operating Interest Expenses was $9000.0 for Q2 2026 at Purple Biotech, down from $31000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $2.1 million in Q4 2023 and troughed at -$69000.0 in Q4 2024.
• A 5-year average of $177500.0 and a median of $27500.0 in 2024 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses surged 11505.56% in 2023 and tumbled 183.33% in 2025, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $18000.0 in 2022, then surged by 11505.56% to $2.1 million in 2023, then slumped by 103.3% to -$69000.0 in 2024, then soared by 410.14% to $214000.0 in 2025, then sank by 95.79% to $9000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $9000.0 (Q2 2026), $31000.0 (Q1 2026), and $214000.0 (Q4 2025), per Business Quant data.